{"product_id":"skin-vrio-analysis","title":"The Beauty Health Company (SKIN): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs The Beauty Health Company (SKIN) truly positioned for long-term success, or are its core strengths just waiting to be replicated? This VRIO analysis cuts straight to the heart of the matter, rigorously testing whether the company's key resources are Valuable, Rare, Inimitable, and Organized to create a sustainable competitive edge. Dive in now to uncover the definitive answer on where The Beauty Health Company (SKIN)'s true power lies and what it means for its future market dominance.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eThe Beauty Health Company (SKIN) - VRIO Analysis: 1. HydraFacial™ Brand Equity \u0026amp; Market Pioneer Status\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at The Beauty Health Company (SKIN) and trying to figure out where the real moat is, especially when recent top-line numbers show some softness. Honestly, the answer isn't in the quarter-over-quarter device sales dip; it’s in the brand equity of HydraFacial. That name recognition is what allows them to command the market, even when macro pressures hit equipment sales.\u003c\/p\u003e\n\n\u003cp\u003eThe brand's pioneer status is a massive asset. They’ve been at this for nearly \u003cstrong\u003e28 years\u003c\/strong\u003e, which is a long time to own the mindshare in a category you essentially created. This history translates directly into pricing power and consumer pull-through. For instance, while Q3 2025 net sales were \u003cstrong\u003e$70.7 million\u003c\/strong\u003e, the resilience of the consumables business - which hit \u003cstrong\u003e71%\u003c\/strong\u003e of net sales - is directly tied to the installed base of \u003cstrong\u003e35,409\u003c\/strong\u003e active machines as of September 30, 2025, all driven by the HydraFacial name.\u003c\/p\u003e\n\n\u003ch3\u003eVRIO Assessment: HydraFacial Brand Equity\u003c\/h3\u003e\n\u003cp\u003eHere’s the quick math on how this brand stacks up against the VRIO criteria. This isn't just about being known; it’s about being the standard.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Dimension\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003cth\u003eSupporting Data\/Implication\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eValue (V)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eDrives premium pricing; the brand is the default choice in hydradermabrasion, supporting a \u003cstrong\u003e64.6%\u003c\/strong\u003e GAAP gross margin in Q3 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eRarity (R)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eFirst-mover status in the category creates a distinct advantage that few competitors can claim.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eInimitability (I)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDifficult\u003c\/td\u003e\n\u003ctd\u003eBrand recognition built over nearly \u003cstrong\u003e28 years\u003c\/strong\u003e and deep provider trust is not something a startup can buy or copy quickly.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eOrganization (O)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eStrong\u003c\/td\u003e\n\u003ctd\u003eManagement consistently focuses on elevating the brand experience and provider loyalty, evidenced by the raised full-year 2025 Adjusted EBITDA guidance range of \u003cstrong\u003e$37 million to $39 million\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSustained\u003c\/td\u003e\n\u003ctd\u003eBrand equity is a deep, hard-to-replicate asset that underpins the recurring consumables revenue stream.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eWhat this estimate hides is the intangible value of being the 'aesthetic gateway' treatment, where \u003cstrong\u003e50 percent\u003c\/strong\u003e of clients purchase an additional treatment or retail product during their visit. That loyalty is brand equity in action.\u003c\/p\u003e\n\n\u003cp\u003eThe strength here is clear. You have a brand that is valuable, rare, and costly to imitate, and the organization is clearly structured to protect it. This is the foundation that allows the company to weather device sales volatility, as seen when Adjusted EBITDA still grew to \u003cstrong\u003e$8.9 million\u003c\/strong\u003e in Q3 2025 despite lower overall sales.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eBrand awareness leads to provider adoption.\u003c\/li\u003e\n\u003cli\u003ePioneer status justifies premium pricing.\u003c\/li\u003e\n\u003cli\u003eConsumer validation drives repeat visits.\u003c\/li\u003e\n\u003cli\u003eLoyalty fuels word-of-mouth referrals.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIf onboarding new providers takes 14+ days, churn risk rises, but the brand equity acts as a buffer against that operational friction.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eThe Beauty Health Company (SKIN) - VRIO Analysis: 2. Proprietary Patent Portfolio\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e2. Proprietary Patent Portfolio\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eProtects the core technology, especially the unique tips and device mechanics, blocking direct imitation. They hold over \u003cstrong\u003e175+\u003c\/strong\u003e patents.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eModerate to High; the sheer volume and successful enforcement (like the August 2025 ITC win) show depth.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eVery Difficult; new patents granted in 2025, like D1084369, keep the moat fresh.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eEffective; the legal team is actively using IP to defend market share against competitors.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eSustained; continuous patenting keeps the technology lead protected.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFinancial and Statistical Data Supporting Patent Portfolio Strength:\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003ePeriod\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eReported Legal Fees Increase due to IP Litigation\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncrease for period ending 12\/31\/2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses (Peak)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.102 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecember 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses (Average over 5 years)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.289 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFiscal years ending December 2020 to 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive Devices in the Field\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e35,193\u003c\/strong\u003e units\u003c\/td\u003e\n\u003ctd\u003eEnd of Q2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Units Placed\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e957\u003c\/strong\u003e units\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe organization's commitment to innovation and defense is reflected in operational metrics:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eConsumable sales for Q2 2025 totaled \u003cstrong\u003e$55.8 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eConsumables as a percentage of revenue remained above \u003cstrong\u003e70%\u003c\/strong\u003e in Q2 2025.\u003c\/li\u003e\n\u003cli\u003eGAAP Gross Margin for Q2 2025 was \u003cstrong\u003e62.8%\u003c\/strong\u003e, compared to \u003cstrong\u003e45.2%\u003c\/strong\u003e in Q2 2024.\u003c\/li\u003e\n\u003cli\u003eAdjusted Gross Margin for Q2 2025 was \u003cstrong\u003e65.9%\u003c\/strong\u003e, compared to \u003cstrong\u003e49.4%\u003c\/strong\u003e in Q2 2024.\u003c\/li\u003e\n\u003cli\u003eOperating expenses were reduced by nearly \u003cstrong\u003e18%\u003c\/strong\u003e in Q2 2025.\u003c\/li\u003e\n\u003cli\u003eCash, cash equivalents, and restricted cash as of June 30, 2025, were approximately \u003cstrong\u003e$212.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eThe Beauty Health Company (SKIN) - VRIO Analysis: 3. High-Margin Consumables Recurring Revenue Model\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides predictable, high-margin revenue.\u003c\/p\u003e\n\u003cp\u003eThe consumables business represented over \u003cstrong\u003e70%\u003c\/strong\u003e of net sales in Q2 2025, with consumable sales totaling \u003cstrong\u003e$55.8 million\u003c\/strong\u003e out of total net sales of \u003cstrong\u003e$78.2 million\u003c\/strong\u003e for the quarter. This recurring revenue stream contributed to an Adjusted Gross Margin of \u003cstrong\u003e65.9%\u003c\/strong\u003e in Q2 2025.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ2 2025 Amount\u003c\/th\u003e\n\u003cth\u003eQ2 2025 Percentage of Net Sales\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Net Sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$78.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e100%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumables Net Sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$55.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\u0026gt;70%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDelivery Systems Net Sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$22.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e~28.6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted Gross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e65.9%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$13.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e17.8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; many medical device companies have this, but the attachment rate here is very high.\u003c\/p\u003e\n\u003cp\u003eThe total active device installed base as of June 30, 2025, was \u003cstrong\u003e35,193 units\u003c\/strong\u003e, up from \u003cstrong\u003e33,504 units\u003c\/strong\u003e in the prior year period. Device placements in Q2 2025 were \u003cstrong\u003e957 units\u003c\/strong\u003e worldwide.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult; requires a large, active installed base to function effectively.\u003c\/p\u003e\n\u003cp\u003eThe model's effectiveness is tied to the installed base utilization, evidenced by the \u003cstrong\u003e36.5%\u003c\/strong\u003e year-over-year decline in global device revenue during Q2 2025, which pressured the overall top line despite strong consumable performance.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Excellent; the entire transformation strategy hinges on driving consumable utilization.\u003c\/p\u003e\n\u003cp\u003eThe company reported operating expenses decreased by \u003cstrong\u003e17.8%\u003c\/strong\u003e to \u003cstrong\u003e$51.8 million\u003c\/strong\u003e in Q2 2025, demonstrating disciplined cost management aligned with the focus on margin-accretive consumables. Cash and Equivalents stood at \u003cstrong\u003e$212 million\u003c\/strong\u003e at the end of Q2 2025 following debt restructuring.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEMEA consumables business grew into the \u003cstrong\u003edouble digits\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eExcluding China, non-APAC consumable sales rose \u003cstrong\u003e5.3%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; the installed base locks in the recurring revenue stream.\u003c\/p\u003e\n\u003cp\u003eThe high proportion of recurring revenue, over \u003cstrong\u003e70%\u003c\/strong\u003e of total net sales, provides a foundation for financial stability and margin expansion, as reflected by the GAAP Gross Margin of \u003cstrong\u003e62.8%\u003c\/strong\u003e in Q2 2025.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eThe Beauty Health Company (SKIN) - VRIO Analysis: 4. Large, Engaged Global Device Install Base\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e This base of over \u003cstrong\u003e35,000\u003c\/strong\u003e devices as of mid-2025 is the engine for consumables sales. Providers delivered approximately \u003cstrong\u003e5 million\u003c\/strong\u003e Hydrafacial treatments last year, translating to \u003cstrong\u003e1.5\u003c\/strong\u003e treatments performed every second globally.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; a large installed base is rare, but the active base tied to consumables is the key metric. The estimated global addressable market for Hydrafacial is more than \u003cstrong\u003e500,000\u003c\/strong\u003e potential locations.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult; requires significant upfront capital and time for providers to adopt.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Good; management's priority is protecting and growing this base.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary to Sustained; it's sustained as long as utilization remains high.\u003c\/p\u003e\n\u003cp\u003eThe installed base underpins the recurring revenue model, as evidenced by the financial contribution of consumables:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ1 2025\u003c\/th\u003e\n\u003cth\u003eQ2 2025\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Delivery Systems Installed (Milestone)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e35,000\u003c\/strong\u003e (as of June 2025)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e35,193\u003c\/strong\u003e (Active Install Base)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive Install Base (Units)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e35,014\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e35,193\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDelivery Systems Net Sales (USD millions)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$20.2\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eData not explicitly provided for Q2 2025 in millions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumables Net Sales (USD millions)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$49.4\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDrove \u003cstrong\u003emore than 70%\u003c\/strong\u003e of revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Net Sales (USD millions)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$69.6\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eData not explicitly provided in millions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDelivery Systems Placed (Units)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e862\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e957\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eKey performance indicators reflecting the engagement and market standing of the device base include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eConsumables net sales represented approximately \u003cstrong\u003e70.97%\u003c\/strong\u003e of total net sales in Q1 2025 ($\\frac{49.4}{69.6}$).\u003c\/li\u003e\n\u003cli\u003eThe active install base grew from \u003cstrong\u003e32,530\u003c\/strong\u003e units in the prior year period (Q1 2024) to \u003cstrong\u003e35,014\u003c\/strong\u003e units as of March 31, 2025.\u003c\/li\u003e\n\u003cli\u003eHydrafacial ranks as the \u003cstrong\u003esecond\u003c\/strong\u003e most recognized facial treatment in the U.S.\u003c\/li\u003e\n\u003cli\u003eConsumer satisfaction is indicated by a \u003cstrong\u003e96%\u003c\/strong\u003e 'Worth It' rating on RealSelf.\u003c\/li\u003e\n\u003cli\u003eThe company reported an industry-leading Net Promoter Score of \u003cstrong\u003e52\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eDelivery system placements decreased to \u003cstrong\u003e957\u003c\/strong\u003e units in Q2 2025 from \u003cstrong\u003e1,285\u003c\/strong\u003e units in Q2 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eThe Beauty Health Company (SKIN) - VRIO Analysis: 5. Operational Discipline \u0026amp; Margin Expansion\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Led to a significant gross margin improvement, hitting \u003cstrong\u003e65.9%\u003c\/strong\u003e adjusted gross margin in Q2 2025. The Q3 2025 GAAP gross margin was \u003cstrong\u003e64.6%\u003c\/strong\u003e, with an Adjusted Gross Margin of \u003cstrong\u003e68.0%\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ2 2025\u003c\/th\u003e\n\u003cth\u003eQ3 2025\u003c\/th\u003e\n\u003cth\u003eQ3 2024\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted Gross Margin (%)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e65.9%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e68.0%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A (Q3 2024 Adjusted GM was 49.4% or 150 bps lower than 68.0%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGAAP Gross Margin (%)\u003c\/td\u003e\n\u003ctd\u003e62.8%\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e64.6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e51.6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Expenses ($ Millions)\u003c\/td\u003e\n\u003ctd\u003e$51.8\u003c\/td\u003e\n\u003ctd\u003e$51.9\u003c\/td\u003e\n\u003ctd\u003eN\/A (Q2 2024 OpEx not explicitly stated)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSelling \u0026amp; Marketing Expenses ($ Millions)\u003c\/td\u003e\n\u003ctd\u003e$23.1\u003c\/td\u003e\n\u003ctd\u003e$20.9\u003c\/td\u003e\n\u003ctd\u003e$27.6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA ($ Millions)\u003c\/td\u003e\n\u003ctd\u003e$13.9\u003c\/td\u003e\n\u003ctd\u003e$8.9\u003c\/td\u003e\n\u003ctd\u003e$8.1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Temporary; cost-cutting efforts are often temporary unless structural changes stick. Structural change: The company closed its China production facility in Q4 2024 and centralized production in the U.S.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Easy; competitors can cut costs, but sustained discipline is harder. Evidence of sustained discipline includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOperating expenses decreased by \u003cstrong\u003e17.8%\u003c\/strong\u003e in Q2 2025 to \u003cstrong\u003e$51.8 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSelling and marketing expenses decreased by \u003cstrong\u003e24.2%\u003c\/strong\u003e in Q2 2025 to \u003cstrong\u003e$23.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eOperating expenses decreased by \u003cstrong\u003e16.5%\u003c\/strong\u003e in Q3 2025 to \u003cstrong\u003e$51.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSelling and marketing expenses decreased by \u003cstrong\u003e24.2%\u003c\/strong\u003e year-over-year in Q3 2025 to \u003cstrong\u003e$20.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong; the transformation program delivered tangible results, with Q3 2025 showing tight cost control. Tangible results include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eQ3 2025 Adjusted EBITDA of \u003cstrong\u003e$8.9 million\u003c\/strong\u003e, an increase from \u003cstrong\u003e$8.1 million\u003c\/strong\u003e in Q3 2024.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Adjusted EBITDA margin improved approximately \u003cstrong\u003e240 basis points\u003c\/strong\u003e to \u003cstrong\u003e12.6%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet Loss reduced to \u003cstrong\u003e$11.0 million\u003c\/strong\u003e in Q3 2025 from \u003cstrong\u003e$18.3 million\u003c\/strong\u003e in Q3 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; this advantage fades once cost savings are fully realized or competitors catch up. The shift to a recurring revenue model supports sustainability:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eConsumable sales for Q2 2025 totaled \u003cstrong\u003e$55.8 million\u003c\/strong\u003e, up \u003cstrong\u003e0.8%\u003c\/strong\u003e year-over-year.\u003c\/li\u003e\n\u003cli\u003eConsumables mix increased to \u003cstrong\u003e71%\u003c\/strong\u003e of net sales in Q3 2025.\u003c\/li\u003e\n\u003cli\u003eTotal active machines in the field increased to \u003cstrong\u003e35,193 units\u003c\/strong\u003e as of June 30, 2025.\u003c\/li\u003e\n\u003cli\u003eTotal active machines in the field increased to \u003cstrong\u003e35,409 units\u003c\/strong\u003e as of September 30, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eThe Beauty Health Company (SKIN) - VRIO Analysis: 6. Multi-Brand Portfolio Expansion\n\u003c\/h2\u003e\n\u003cp\u003eThe multi-brand strategy diversifies revenue streams beyond the core Hydrafacial™ platform, incorporating specialized modalities such as SkinStylus™ for microneedling and Keravive™ for scalp health.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Diversifies risk away from a single treatment modality, including SkinStylus™ (microneedling) and Keravive™ (scalp health). The installed base of devices supports a recurring revenue model, with consumables driving \u003cstrong\u003emore than 70%\u003c\/strong\u003e of revenue as of Q2 2025, supported by over \u003cstrong\u003e35,000\u003c\/strong\u003e active devices in the field.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; many beauty\/medtech firms have multiple brands, but the established market position of Hydrafacial™, SkinStylus™, and Keravive™ within their respective adjacencies provides a degree of rarity.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; building brand equity in new segments like scalp health (Keravive™) takes time and marketing spend. The successful launch of the HydraFillic with Pep9™ Booster, which saw \u003cstrong\u003e100 percent\u003c\/strong\u003e of participants report an improvement in skin firmness, demonstrates the ability to create high-value, proprietary consumables that are difficult to replicate instantly.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Developing; new product launches like HydraFillic with Pep9™ Booster show innovation is active. The company reported Q2 2025 Adjusted EBITDA of \u003cstrong\u003e$13.9m\u003c\/strong\u003e, an \u003cstrong\u003e$8.7m\u003c\/strong\u003e increase on the same period the previous year, indicating organizational focus on profitability aligned with strategic goals.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; it offers a chance to build new sustained advantages over time through the continued introduction of high-efficacy consumables that leverage the installed base.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\/Result\u003c\/td\u003e\n\u003ctd\u003eContext\/Period\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumables Revenue Share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\u0026gt;70%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive Device Placements\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e35,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHydraFillic Booster Firmness Improvement\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e100%\u003c\/strong\u003e reported improvement\u003c\/td\u003e\n\u003ctd\u003ePost-treatment clinical perception\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHydraFillic Booster Glow Improvement\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e96%\u003c\/strong\u003e reported improvement\u003c\/td\u003e\n\u003ctd\u003ePost-treatment clinical perception\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ2 2025 Net Sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eUS$78.2m\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCompared to $90.6m in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ2 2025 Adjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$13.9m\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$8.7m increase YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cul\u003e\n\u003cli\u003eThe successful launch of the HydroLoc booster in Q3 2024 was noted as the most successful Hydrafacial branded booster launch to date, selling out in record time.\u003c\/li\u003e\n\u003cli\u003eThe company's Q3 2024 gross margin improved to \u003cstrong\u003e51.6%\u003c\/strong\u003e from a negative margin of \u003cstrong\u003e(12.9)%\u003c\/strong\u003e in Q3 2023, driven by product cost management and the shift to consumables.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eThe Beauty Health Company (SKIN) - VRIO Analysis: 7. Global Professional Provider Community Network\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides a direct channel for training, education, and driving adoption among estheticians and clinics.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; a large, trained network is a significant barrier to entry for new players.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult; requires years of relationship building and training infrastructure.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Focused; management is investing in education and training to leverage this community.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; the network effect of trained professionals is sticky.\u003c\/p\u003e\n\u003cp\u003eThe commitment to the professional community is quantified by specific metrics related to scale and educational investment:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe Beauty Health Company aims to be the \u003cstrong\u003e#1 global educator\u003c\/strong\u003e of beauty health professionals.\u003c\/li\u003e\n\u003cli\u003eAs of October 2023, the company had trained \u003cstrong\u003emore than 40,000 estheticians worldwide\u003c\/strong\u003e through proprietary programs.\u003c\/li\u003e\n\u003cli\u003eThe company operates and personalizes skin health across its community in \u003cstrong\u003emore than 90 countries\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe professional network utilizes the technology, evidenced by an active install base of \u003cstrong\u003e35,409\u003c\/strong\u003e delivery systems as of September 30, 2025.\u003c\/li\u003e\n\u003cli\u003eThe esthetician profession, a core part of this network, is expected to grow by \u003cstrong\u003e+9% through 2032\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe investment in the professional channel is a key component of the company's 'push' marketing strategy, engaging directly with providers.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eDate\/Period Reference\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstheticians Trained (Cumulative)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eMore than 40,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of October 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive Device Install Base\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e35,409\u003c\/strong\u003e units\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeographic Reach (Community)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eMore than 90\u003c\/strong\u003e countries\u003c\/td\u003e\n\u003ctd\u003eRecent reporting\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEsthetician Profession Growth Projection\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e+9%\u003c\/strong\u003e through 2032\u003c\/td\u003e\n\u003ctd\u003eProjected\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe training infrastructure supports the installed base, which is critical for recurring consumable revenue:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe active install base was reported at \u003cstrong\u003e35,014\u003c\/strong\u003e units as of March 31, 2025.\u003c\/li\u003e\n\u003cli\u003eThe company utilizes data and input from its global network of professional skin health providers to inform its Skintuition Report.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eThe Beauty Health Company (SKIN) - VRIO Analysis: 8. U.S. Production Relocation \u0026amp; Supply Chain De-risking\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Mitigates geopolitical and tariff risk, which was a major concern, while improving gross margin. The relocation of production to the U.S. and the transition of China operations to a distributor model are cited as decisive actions to expand profit margins.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003ePeriod Ended March 31, 2024 (Q1 2024)\u003c\/th\u003e\n\u003cth\u003ePeriod Ended March 31, 2025 (Q1 2025)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin (GAAP)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e59.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e69.8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted Gross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e63.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e71.9%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe shift in operational footprint contributed to an increase in Adjusted Gross Margin from \u003cstrong\u003e63.4%\u003c\/strong\u003e in Q1 2024 to \u003cstrong\u003e71.9%\u003c\/strong\u003e in Q1 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Temporary; this was a strategic reaction to macro risks, not an inherent advantage. The company closed its China production facility in Q4 2024.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; other companies can move production, but it involves capital expenditure and time. The transition of China operations to a distributor model was initiated in Q2 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Decisive; the transition of the China operation to a distributor model shows agility. The company took decisive actions to expand profit margins.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company completed the transition of its China market from a direct sales to a distributor model in the second quarter of 2025.\u003c\/li\u003e\n\u003cli\u003eThe company closed its China production facility in Q4 2024 and centralized production in the U.S.\u003c\/li\u003e\n\u003cli\u003eIn Q3 2025, consumables revenue was $49.8 million, with the consumable mix rising to \u003cstrong\u003e71%\u003c\/strong\u003e of net sales when excluding the China impact.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; the benefit is realized once the new supply chain is fully optimized. The transition to a distributor model in China helped streamline inventory and reduce exposure to tariffs.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eThe Beauty Health Company (SKIN) - VRIO Analysis: 9. Recent Financial Turnaround \u0026amp; Raised Guidance\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Demonstrates management confidence and operational leverage, raising 2025 adjusted EBITDA guidance to \u003cstrong\u003e$37M–$39M\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Temporary; financial performance is inherently cyclical and dependent on macro factors. \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Easy; competitors aim for this every quarter. \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong; exceeding expectations in Q2 and Q3 2025 shows alignment between strategy and execution. \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; this is a result, not a resource, and must be repeated to become sustained. \u003c\/p\u003e\n\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cp\u003eThe financial turnaround is evidenced by consecutive quarters exceeding initial guidance and subsequent upward revisions to full-year forecasts.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ2 2025 Actual\u003c\/th\u003e\n\u003cth\u003eQ3 2025 Actual\u003c\/th\u003e\n\u003cth\u003eRaised FY 2025 Guidance\u003c\/th\u003e\n\u003cth\u003eQ3 2025 Guidance\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$78.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$70.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$293 million to $300 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$65 million to $70 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$13.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$37 million to $39 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2 million to $4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGAAP Gross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e62.8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e64.6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eKey performance indicators demonstrating operational leverage and execution:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eQ2 2025 revenue of \u003cstrong\u003e$78.2 million\u003c\/strong\u003e and Adjusted EBITDA of \u003cstrong\u003e$13.9 million\u003c\/strong\u003e beat internal expectations.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 revenue of \u003cstrong\u003e$70.7 million\u003c\/strong\u003e and Adjusted EBITDA of \u003cstrong\u003e$8.9 million\u003c\/strong\u003e exceeded the top end of the guidance range.\u003c\/li\u003e\n\u003cli\u003eGAAP Gross Margin improved to \u003cstrong\u003e62.8%\u003c\/strong\u003e in Q2 2025 from \u003cstrong\u003e45.2%\u003c\/strong\u003e YoY, and further to \u003cstrong\u003e64.6%\u003c\/strong\u003e in Q3 2025 from \u003cstrong\u003e51.6%\u003c\/strong\u003e in Q3 2024.\u003c\/li\u003e\n\u003cli\u003eConsumables net sales in Q2 2025 totaled \u003cstrong\u003e$55.8 million\u003c\/strong\u003e, representing over \u003cstrong\u003e70%\u003c\/strong\u003e of revenue.\u003c\/li\u003e\n\u003cli\u003eTotal active machines in the field increased to \u003cstrong\u003e35,193 units\u003c\/strong\u003e as of Q2 2025, up from \u003cstrong\u003e33,504 units\u003c\/strong\u003e at the end of Q2 2024.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 net loss of \u003cstrong\u003e$(11.0) million\u003c\/strong\u003e, an improvement from a net loss of \u003cstrong\u003e$(18.3) million\u003c\/strong\u003e in Q3 2024.\u003c\/li\u003e\n\u003cli\u003eCash, cash equivalents, and restricted cash were approximately \u003cstrong\u003e$219 million\u003c\/strong\u003e as of September 30, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516251332757,"sku":"skin-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/skin-vrio-analysis.png?v=1740221828","url":"https:\/\/dcf-model.com\/fr\/products\/skin-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}